SCHEMBL5324671

SCHEMBL5324671

Cc1ccc(S(=O)(=O)OC(Cc2ccccc2)(Cc2ccccc2)P(=O)(O)O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
FDPS P14324 1/20 0.44
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42
CA12 O43570 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
ATM Q13315 1/20 0.42
CA9 Q16790 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 2/20 0.41
PTPN1 P18031 1/20 0.41
MCHR1 Q99705 1/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 1/20 0.39
TP53 P04637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
TAS2R14 Q9NYV8 1/20 0.39
VDR P11473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL156226 0.81 MMP2 (0.41) LMNACA12CYP3A4CA9PTPN1
SCHEMBL7993483 0.78 BCHE (0.45) LMNABCHEACHECA12CYP1A2
SCHEMBL605141 0.78 PPARG (0.47) LMNABCHEACHECA12CYP1A2
SCHEMBL7354211 0.77 BCHE (0.44) LMNABCHEACHECA12CYP1A2
SCHEMBL7334079 0.75 FDPS (0.50) FDPSPTPN1
SCHEMBL10710616 0.75 BCHE (0.40) LMNABCHEACHECA12CYP1A2
SCHEMBL23581205 0.72 MMP2 (0.46) LMNABCHEACHECA12CYP1A2
SCHEMBL22945552 0.71 BCHE (0.41) LMNABCHEACHECA12CYP1A2
SCHEMBL16020646 0.71 TSHR (0.47) LMNABCHEACHECA12CYP1A2
SCHEMBL6230138 0.71 RECQL (0.49) LMNAMAPTKMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007112348-A2 PRODRUG COMPOSITION TSRL, INC. (US) 2007-10-04 WO disclosed
US-20070167353-A1 PRODRUG COMPOSITION THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2007-07-19 US disclosed
US-20050137141-A1 Prodrug composition HILFINGER JOHN (US) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167353-A1 PRODRUG COMPOSITION ADA, SLC29A1, SLC29A2 LMNA 3606/4885FDPS 824/4885BCHE 707/4885
US-20050137141-A1 Prodrug composition CYP3A5, SLC35B2, SLC1A5 LMNA 3095/4885FDPS 994/4885BCHE 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.